Qinqin Cheng

Qinqin Cheng

Auto-generated profile, based on publicly available information

Qinqin Cheng

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
QCQinqin Cheng
Qinqin Cheng
XSXiaojing Shi
Xiaojing Shi
MHMenglu Han
Menglu Han
GSGoar Smbatyan
Goar Smbatyan
HLHeinz-Josef Lenz
Heinz-Josef Lenz
YZYong Zhang
Yong Zhang

1 February 2020 in Molecular Therapy
Verified
Journal Article
Open access
XSXiaojing Shi
Xiaojing Shi
QCQinqin Cheng
Qinqin Cheng
THTianling Hou
Tianling Hou
MHMenglu Han
Menglu Han
GSGoar Smbatyan
Goar Smbatyan
YZYong Zhang
Yong Zhang
Exosomes are nanosized membranous vesicles secreted by a variety of cells. Due to their unique and pharmacologically important properties, cell-derived exosome nanoparticles have drawn significant interest for drug development. By genetically modifying exosomes with two distinct types of surface-displayed monoclonal antibodies, we have developed an exosome platform termed synthetic multivalent antibodies retargeted exosome (SMART-Exo) for controlling cellular immunity. Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors. By redirecting and activating cytotoxic T cells toward attacking HER2-expressing breast cancer cells, the designed SMART-Exos exhibited highly potent and specific anti-tumor activity both in vitro and in vivo. This work demonstrates preclinical feasibility of utilizing endogenous exosomes for targeted breast cancer immunotherapy and the SMART-Exos as a broadly applicable platform technology for the development of next-generation immuno-nanomedicines.

28 February 2014 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
QCQinqin Cheng
Qinqin Cheng
HSHongdong Shi
Hongdong Shi
HWHongxia Wang
Hongxia Wang
YMYuanzeng Min
Yuanzeng Min
JWJun Wang
Jun Wang
YLYangzhong Liu
Yangzhong Liu
Asplatin, a fusion of aspirin and cisplatin, exhibits significant synergistic-effects on tumor cells and cisplatin-resistant cells.

20 April 2016 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
QCQinqin Cheng
Qinqin Cheng
YLYangzhong Liu
Yangzhong Liu

1 July 2016 in Biomaterials
Verified
Journal Article
Closed access
ZCZhi-Ting Cao
Zhi-Ting Cao
ZCZhi-Yao Chen
Zhi-Yao Chen
CSChun-Yang Sun
Chun-Yang Sun
HLHongjun Li
Hongjun Li
HWHong-Xia Wang
Hong-Xia Wang
JWJun Wang
Jun Wang

25 September 2015 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HSHongdong Shi
Hongdong Shi
QCQinqin Cheng
Qinqin Cheng
SYSiming Yuan
Siming Yuan
XDXin Ding
Xin Ding
YLYangzhong Liu
Yangzhong Liu